Cryocompression May Mitigate Chemo-Induced Neuropathy in Gynecologic Cancers

Video

Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.

Cryocompression may help to prevent peripheral neuropathy related to chemotherapy for patients diagnosed with gynecologic cancers without additional burden, according to Mary Katherine Montes de Oca, MD.

During The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, about data from a study evaluating the efficacy and patient-reported outcomes of cryocompression in preventing peripheral neuropathy following chemotherapy for gynecologic cancers as well as patient-reported.

In the self-controlled trial, over 70% of patients reported cryocompression was very tolerable with each cycle, and over 80% “agreed” or “strongly agreed” that cryocompression was acceptable and planned to continue with the intervention during future chemotherapy. Additionally, patients undergoing cryocompression were 39% less likely to report Patient Neurotoxicity Questionnaire grade of C or less symptoms of peripheral neuropathy compared with a control group of patients who did not undergo cryocompression.

Transcript:

We found that cryocompression therapy significantly prevented subjective symptoms of neuropathy. We didn’t find any differences in objective neuropathy between groups, and we found that patients overall were able to tolerate the cryocompression really well.

There’s a theoretical concern of frostbite from the ice on the hands and feet. We didn’t have any adverse [effects] from use of the cryocompression. There were 2 patients who weren’t able to tolerate the treatment. But the compression therapy can also allow for a barrier between the patient’s fingertips and the ice.

I hope that [my colleagues] take away that cryocompression can prevent chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Hopefully, it is something that is easy, accessible, and [is something] that can be recommend to patients without creating additional burden on them during chemotherapy.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Related Content